Clinical trial

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-06-01

PhasePHASE4

Study timeline

Study start (actual)2008-06-01Date precision: month

Registry last updated2019-09-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Schizoaffective Disorderunresolved

Interventions

AcamprosateDRUG · verified · RxNorm: acamprosate

Sponsors & collaborators

University of Maryland, Baltimorelead sponsor

National Alliance for Research on Schizophrenia and Depressioncollaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)collaborator

Mapped research locations

BaltimoreMaryland, United States4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00688324 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.